Bristol-Myers axes 107 more staffers as it completes an R&D overhaul

Wallingford, CT site

Winding down its R&D ops in Wallingford, CT, Bristol-Myers Squibb $BMY has put its remaining workers on notice that it’s axing 107 staffers in the next step of the big revamp.

The biopharma giant said more than a year ago that it would shutter its big facility in the state, while also reversing a decision to try and relocate workers to some other facility in the state.

That reorganization includes expanding operations in Lawrenceville and New Brunswick, NJ and Redwood City, CA, and opening a new research site in Cambridge, MA.

The latest cuts will be completed by early April, Bristol-Myers noted in a WARN statement filed with the state.

Local press reports say that Bristol-Myers has cut its workforce in Wallingford in half, with about 400 left now as it prepares to exit Connecticut by the end of this year. The company once employed 800 at the site.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->